Thinking About Switching? Read Real Omnipod® Reviews from People Who Did
Switching diabetes technology isn’t a small decision.
Many people considering Omnipod tell us they ask the same questions:
- Will it fit my lifestyle?
- Is it complicated to use?
- What if it doesn’t work for me?
- Will I miss what I’m using now?
These stories come from people who asked those exact questions and decided to switch.
Featured Stories: Meet Barbara and Josh
“I found that the Pod enabled me to think in a more relaxed way, it’s been an assistance to me in a great way. It has improved my time in range”
Barbara, Brisbane, Podder® since 2025
“My life is happier now. I think more rewarding. I can go about my life with a simpler sort of idea around my diabetes management. I don't have to worry as much about the maintenance for the (Daily) insulin injections. It's a lot more accessible when I'm eating, loading my insulin. It's just it's easier. "
Josh, Gold Coast, Podder® since 2025
Experience Omnipod® for yourself
Take the first step toward tubeless, automated insulin delivery. Whether you want to try it, see it, or talk it through, there’s an option that works for you.
More stories about switching to Omnipod® 5
Switching from multiple daily injections
“I have far better control; I am no longer afraid of going to sleep at night, I feel like I have my life back again, which is really nice”
Monique, QLD, Podder® since 2025
Switching from a tubed pump
“When I first heard about Omnipod, one of the things I noticed straight away, it was a lot easier, it’s a lot of the little things you don’t notice. It’s really great”
Scott, Brisbane, Podder® since 2023
Switching as a parent or caregiver
“All round for the whole family – it was like a weight had been lifted off of our shoulders.”
Gill, mum of Ella, Gold Coast, Podder® since 2025
After 18 months on multiple daily injections, Priya moved onto the Omnipod DASH® and then upgraded to the Omnipod 5 once it was released in Australia in 2025. The freedom Omnipod has provided us has been life changing. It’s allowed Priya to just focus on being a kid and has given us as parents the peace of mind that her levels are sitting at a healthy level more often.
Kimmie, mum of Priya, Melbourne, Podder® since 2024
Omnipod® 5: Increase Time in Range1,2
& Simplify Life®
More time spent in range
Over 80% Time in Range with optimised settings.3
3. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.
Helps correct highs and protect from low
Omnipod 5 automatically adjusts insulin delivery every 5 minutes day and night.
Supports a better quality of life
People using Omnipod 5 stress less about their diabetes.
Ready to explore Omnipod for yourself?
Take the first step toward tubeless, automated insulin delivery. Watch a live demo or try a demo Pod* to see how it could fit into your life.
* The demo Pod is a needle-free, non-functioning Pod. PDM/Controller is not included.
Thousands have already taken the next step
Head to our socials to explore real stories, see how Omnipod® fits into everyday life, and understand what it’s really like to make the change.
Tik Tok
1. Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 - 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (3.9-10.0 mmol/L or 70- 180mg/dL) in adults/adolescents as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001. Mean time in range (3.9-10.0 mmol/L or 70-180mg/dL) in children as measured by CGM: ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in adults/adolescents and children ST vs. 3-mo Omnipod 5: 28.9% vs. 22.8%; 44.8% vs 29.7%, P<0.0001, respectively. Mean time in hypoglycaemic range in adults/adolescents (<3.9 mmol/L or <70mg/dL as measured by CGM) as measured by CGM: ST = 1.89%, 3- mo Omnipod 5 = 1.32%, P<0.0001. Mean time in hypoglycaemic range in children (<3.9 mmol/L or <70mg/dL as measured by CGM): ST = 2.21%, 3-mo Omnipod 5 = 1.78%, P<0.0456.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3- month AID phase with Omnipod 5 system. Mean time in range (3.9-10.0 mmol/L or 70- 180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs. 29.5%, P<0.0001, respectively. Mean time in hypoglycaemic range (<3.9mmol/L or <70mg/dL as measured by CGM) ST = 3.43% vs Omnipod 5: 2.46%, P<0.0001.
3. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.
2. Sherr J. et al. Diabetes Care. 2022; 45:1907-1910. Single-arm multicenter clinical trial in 80 pre-school children (aged 2-5.9 yrs) with T1D. Study included a 14-daystandard therapy (ST) phase followed by a 3- month AID phase with Omnipod 5 system. Mean time in range (3.9-10.0 mmol/L or 70- 180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 57.2% vs 68.1%, P<0.0001. Mean time in hyperglycaemic range (>10.0 mmol/L or >180mg/dL) as measured by CGM in children ST vs. 3-mo Omnipod 5: 39.4% vs. 29.5%, P<0.0001, respectively. Mean time in hypoglycaemic range (<3.9mmol/L or <70mg/dL as measured by CGM) ST = 3.43% vs Omnipod 5: 2.46%, P<0.0001.
3. Retrospective RWE data on file. 2025. Results shown for users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥5 bolus/day and an average Target Glucose of 110-115 mg/dL (6.1-6.4 mmol/L). Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014.